CD8A and myeloid sarcoma: Indeed, even though observed in a single MS patient and not confirmed at the TCR level, the autoBLCL-reactive CD8+ T-cell response in the paired mAIL-TCL of this particular MS patient was dominated by TCRVβ2+ CD8+ T cells.